Testosterone Undecanoate Oral (Jatenzo)

Quick Reference Card

Overview / What Is Testosterone Undecanoate Oral (Jatenzo)?

The Basics

Jatenzo is a prescription oral testosterone capsule designed to replace testosterone in men whose bodies can no longer produce enough on their own. Unlike the older oral testosterone pills that were pulled from common use due to liver damage, Jatenzo uses a fundamentally different absorption pathway that bypasses the liver entirely, entering your bloodstream through the intestinal lymphatic system instead.

Think of it this way: older oral testosterone pills went straight to the liver before reaching your bloodstream, which is like running a package through a shredder before delivery. Jatenzo, by contrast, takes a side road (the lymphatic system) that avoids the liver entirely. This is why it does not carry the liver toxicity concerns that gave oral testosterone a bad reputation for decades.

Jatenzo was approved by the FDA in March 2019, making it the first oral testosterone undecanoate in the United States to use a self-emulsifying drug delivery system (SEDDS). It is taken twice daily with food, once in the morning and once in the evening, and comes in three capsule strengths: 158 mg (red), 198 mg (white), and 237 mg (orange). Your provider will adjust your dose based on blood tests taken 6 hours after the morning dose.

Like all testosterone products, Jatenzo is a Schedule III controlled substance indicated specifically for men diagnosed with primary or hypogonadotropic hypogonadism, not for age-related testosterone decline, which remains an off-label and not-yet-established use.

The Science

Jatenzo (NDA206089) contains testosterone undecanoate, a fatty-acid ester of testosterone (C30H48O3, MW 456.7) formulated in a self-emulsifying drug delivery system. The SEDDS formulation combines hydrophilic and lipophilic excipients (oleic acid, polyoxyl 40 hydrogenated castor oil, borage seed oil, peppermint oil, BHT) within a soft gelatin capsule to promote intestinal lymphatic absorption via chylomicron incorporation [1].

This absorption pathway distinguishes Jatenzo from the 17-alpha-alkylated oral androgens (methyltestosterone, fluoxymesterone) that predominated in earlier decades. Those compounds survived hepatic first-pass metabolism through their alkyl modification but at the cost of dose-dependent hepatotoxicity including cholestatic jaundice, peliosis hepatis, and hepatocellular carcinoma. In one historical cohort of 60 patients receiving methyltestosterone (50 mg three times daily), 32% developed abnormal liver function tests and 63% had abnormal liver scans [2].

Jatenzo's development program spanned more than 10 years, including Phase 1, 2, and 3 studies. The application was submitted through the FDA's 505(b)(2) pathway and approved on March 27, 2019, with Clarus Therapeutics as the original applicant [3]. The product was subsequently acquired by TOLMAR Inc. The July 2025 label revision removed the boxed warning for blood pressure increases, removed the contraindication for "age-related hypogonadism," and removed the separate cardiovascular risk warning section [1].

Medical / Chemical Identity

Inactive Ingredients

Capsule fill: oleic acid, polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), borage seed oil, peppermint oil, butylated hydroxytoluene (BHT).

Capsule shell: gelatin, sorbitol, glycerin, purified water, iron oxide red, FD&C Yellow #6, titanium dioxide.

Ester Chemistry

Testosterone undecanoate features an undecanoic acid (11-carbon) ester chain attached to the 17-beta hydroxyl group of testosterone. This long-chain fatty acid ester promotes lipophilicity, enabling incorporation into intestinal chylomicrons during digestion and subsequent lymphatic transport. After lymphatic absorption, non-specific tissue and plasma esterases cleave the undecanoate side chain to release free, bioactive testosterone [1][2].

The undecanoate ester is the same ester used in the long-acting injectable formulation (Aveed/Nebido), though the oral and injectable forms have completely different pharmacokinetic profiles due to their different absorption mechanisms. The oral SEDDS formulation is specifically designed for intestinal lymphatic uptake, while the injectable oil-based formulation relies on slow release from an intramuscular depot.

How It Works / Mechanism of Action

The Basics

When you swallow a Jatenzo capsule with food, the self-emulsifying system breaks down in your gut and mixes with the fats from your meal. This combination gets packaged into tiny fat-carrying particles called chylomicrons, which are absorbed through the lymphatic vessels in your intestinal wall rather than going through the liver's portal vein like most medications. This lymphatic absorption pathway is why Jatenzo avoids the liver toxicity that plagued older oral testosterone products.

Once the testosterone undecanoate reaches your bloodstream via the lymphatic system, enzymes throughout your body clip off the undecanoate ester chain, releasing free testosterone. This free testosterone then does what testosterone naturally does: it binds to androgen receptors in tissues throughout your body, including muscle, bone, brain, and reproductive organs. Some testosterone also gets converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, or to estradiol by the enzyme aromatase. Both of these conversions are normal and serve important physiological functions.

Because Jatenzo relies on the fats in your meal to initiate absorption, taking it without food dramatically reduces how much testosterone actually reaches your bloodstream. This is not an optional recommendation; it is a fundamental requirement of the drug's mechanism.

The Science

Testosterone undecanoate in the SEDDS formulation undergoes intestinal lymphatic absorption via chylomicron incorporation, bypassing hepatic first-pass metabolism. The absorption mechanism involves three key steps: (1) self-emulsification of the lipid-based formulation upon contact with gastrointestinal fluids and dietary fat, (2) solubilization of testosterone undecanoate within mixed micelles and subsequent incorporation into chylomicrons during enterocyte processing, and (3) chylomicron transport via intestinal lacteals into the thoracic duct and systemic circulation [1][4].

Dietary fat content significantly influences absorption. A meal containing 15 g of fat decreases exposure by approximately 25% compared to a 30 g fat meal. Fasting conditions dramatically reduce bioavailability, as chylomicron formation requires dietary lipid as a trigger [5]. This food-dependent absorption creates meaningful intra- and inter-patient variability in serum testosterone levels.

Following systemic entry, testosterone undecanoate undergoes ester hydrolysis by non-specific esterases in plasma and tissues to release free testosterone. Testosterone binds to intracellular androgen receptors, initiating both genomic signaling (transcription factor activity) and non-genomic rapid signaling pathways. Approximately 40% of circulating testosterone is bound to sex hormone-binding globulin (SHBG), with the remainder bound to albumin or circulating as free testosterone [5].

Testosterone metabolism proceeds through two primary enzymatic pathways: 5-alpha reduction to DHT (a more potent androgen) and aromatization to estradiol (an estrogen). Excretion occurs primarily as urinary glucuronide and sulfate conjugates [1].

Historical Context

Oral testosterone therapy has a complicated history. The earliest oral androgens, particularly methyltestosterone (developed in the 1930s) and fluoxymesterone, used 17-alpha-alkylation to survive hepatic first-pass metabolism. While effective at raising testosterone levels, these compounds caused dose-dependent liver damage ranging from cholestatic jaundice and peliosis hepatis to hepatic adenomas and hepatocellular carcinoma with long-term use [2].

The development of oral testosterone undecanoate in the 1970s represented the first major advance, leveraging lymphatic absorption to avoid the liver. The earliest oral TU product, Andriol, was approved in many countries outside the United States but never received FDA approval due to high variability in absorption (requiring very high-fat meals) and inconsistent serum testosterone levels [4].

Jatenzo's innovation was the self-emulsifying drug delivery system, which improved and standardized the lymphatic absorption process, making oral testosterone undecanoate viable for the US market. After a development program spanning more than a decade, Jatenzo received FDA approval on March 27, 2019, becoming the first oral testosterone approved in the United States since methyltestosterone. Two additional oral testosterone undecanoate products followed: Tlando (fixed dose, approved 2022) and Kyzatrex (titratable, approved 2022) [5].

Pharmacokinetics / Hormone Physiology

The Basics

Jatenzo behaves very differently from injectable testosterone in terms of how it moves through your body. Instead of the slow, steady release from an oil depot in your muscle, Jatenzo delivers testosterone in a pulsed pattern that rises after each dose and then falls before your next one. This creates a daily rhythm with two peaks (after morning and evening doses) and two troughs (overnight and mid-afternoon).

The practical implication is that your testosterone levels on Jatenzo are never constant. They peak around 2 to 5 hours after you take the capsule with food and decline over the following hours. This is why lab timing matters so much: your blood draw should be exactly 6 hours after the morning dose, which captures the declining phase and gives your provider a standardized reference point for dose adjustment.

How much fat is in your meal when you take Jatenzo makes a real difference in how much testosterone you absorb. A meal with only 15 grams of fat results in about 25% less absorption than a meal with 30 grams. Some individuals have found that taking the capsule alongside a fat source like peanut butter or fish oil capsules helps maximize absorption.

The Science

Following oral administration with food, testosterone undecanoate in the SEDDS formulation is absorbed via intestinal lymphatics with peak serum testosterone concentrations (Cmax) typically reached 2 to 5 hours post-dose. The mean time-averaged testosterone concentration (Cavg) following dose titration is approximately 403 ng/dL, with a mean Cmax of approximately 1008 ng/dL in the pivotal inTUne trial [1][5].

Absorption is critically food-dependent. Fat content modulates chylomicron formation: a 15 g fat meal decreases testosterone AUC by approximately 25% compared to a 30 g fat meal [5]. Fasting administration dramatically reduces bioavailability, with Tlando (a related oral TU product) showing 38% reduction in AUC and 65% reduction in Cmax under fasting conditions [5].

Comparative pharmacokinetics of oral TU products:

Distribution: approximately 40% of circulating testosterone is bound to SHBG, with the remainder bound to albumin or free. Metabolism occurs via ester hydrolysis to testosterone, followed by 5-alpha reduction to DHT and aromatization to estradiol. Excretion is primarily through urinary conjugates [1][5].

The oral TU products are not bioequivalent and cannot be substituted for one another. Each has unique pharmacokinetics, dosing protocols, and titration requirements. Switching between products requires re-titration and monitoring of serum testosterone [5].

Understanding how your specific oral testosterone formulation is absorbed, how long it stays active, and how food affects those dynamics can help you work with your provider to optimize your protocol. Doserly lets you log every dose with ester-specific detail, building a clear record of your testosterone protocol over time.

Whether you're on cypionate twice weekly, enanthate every 3.5 days, or undecanoate every ten weeks, the app tracks your schedule and flags when your next dose is due. When your provider asks how your protocol has been going, you'll have a precise answer instead of a best guess.

Research & Clinical Evidence

The Basics

The clinical evidence for Jatenzo centers on one pivotal trial and its extensions, plus a growing body of comparative reviews published since three oral TU products entered the market.

The key study, called the inTUne trial, enrolled 166 men with confirmed hypogonadism (ages 18-75, average age 56.2) and followed them for up to two years. The headline result: 87% of men achieved testosterone levels within the normal (eugonadal) range after dose titration. Beyond just normalizing lab numbers, the men reported meaningful improvements in sexual desire, sexual activity, and overall sexual function using validated questionnaires. These improvements held steady through the full 24 months of follow-up [1][5].

The inTUne trial also measured changes in body composition and bone density. Over one year, men on Jatenzo gained an average of 3.15 kg of lean body mass and showed measurable increases in bone mineral density at both the spine and hip. These are clinically meaningful outcomes, especially for men who came into the study with low muscle mass or at risk for osteoporosis [5].

One important caveat: the inTUne trial was open-label (no placebo group) and had no comparator arm (no head-to-head with injections or gel). This means the 87% efficacy rate tells us Jatenzo works, but it does not tell us whether it works better, worse, or the same as other TRT options. No large randomized controlled trial has directly compared oral TU to injectable or transdermal testosterone.

The Science

Pivotal inTUne Trial:
The multicenter, open-label, single-arm Phase 3 trial (inTUne) enrolled 166 hypogonadal men (mean age 56.2 years, 87% White) for an initial 4-month efficacy period with a 12-month safety extension. Participants were started on 237 mg BID with dose titration between 158 and 396 mg BID based on serum testosterone measured 6 hours post-morning dose. The primary endpoint was the proportion of men achieving Cavg within the eugonadal range (300-1000 ng/dL) [1][6].

Results: 87% of evaluable participants achieved the primary endpoint. Of 129 eligible extension participants, 86 enrolled and 69 completed 24 months of continuous therapy. Efficacy was sustained throughout the extension period [6][7].

Psychosexual outcomes: Sustained improvements in Psychosexual Daily Questionnaire scores for sexual activity, desire, and function through 24 months [7].

Body composition and bone density: Lean body mass increased by 2.87 +/- 2.73 kg at 180 days and 3.15 +/- 2.69 kg at 365 days (p < 0.0001). Spine bone mineral density increased by 0.013 +/- 0.035 g/cm2 at 180 days and 0.018 +/- 0.042 g/cm2 at 365 days. Hip BMD increased by 0.006 +/- 0.019 g/cm2 at 180 days and 0.012 +/- 0.023 g/cm2 at 365 days (all p < 0.0001 vs baseline) [8].

TRAVERSE trial context: The TRAVERSE trial (n=5,246), the largest RCT powered for cardiovascular outcomes, tested testosterone gel (not oral TU) vs placebo in men 45-80 with cardiovascular risk factors. The primary composite endpoint of major adverse cardiovascular events (MACE) showed non-inferiority: HR 0.96 (95% CI: 0.78-1.17) over a mean 33-month follow-up [9]. While TRAVERSE did not study oral TU specifically, it provides the strongest cardiovascular safety evidence for testosterone replacement therapy as a class.

Study limitations: All pivotal trials for Jatenzo, Tlando, and Kyzatrex are open-label, single-arm studies without placebo or active comparator arms. This limits the ability to attribute outcomes solely to the drug and prevents direct efficacy or safety comparison across formulations. No large RCT has compared oral TU to injectable or transdermal testosterone [5].

Evidence & Effectiveness Matrix

Benefits & Therapeutic Effects

The Basics

For men with confirmed testosterone deficiency, Jatenzo offers several potential benefits that go beyond simply raising a number on a lab report. In the clinical trial, men reported improved sexual desire and function that held steady for two full years. Their bodies gained lean muscle mass and increased bone density at the spine and hip. These are outcomes that matter for daily life, especially for men who came into treatment feeling weak, fatigued, or concerned about long-term bone health.

The oral route itself is a benefit for some men. There are no needles, no risk of accidental transfer to a partner or child (a real concern with testosterone gels), and no need for periodic pellet implant procedures. For men who have had poor experiences with injections or gels, or who cannot use those formulations for medical reasons, having a pill option is genuinely valuable.

There are also early clinical signals that oral testosterone may produce less erythrocytosis (excess red blood cell production) than longer-acting injectable formulations. If confirmed in larger studies, this could make oral TU a preferred option for men who have experienced hematocrit elevations on injections.

The Science

Documented benefits from clinical trials [1][5][6][7][8]:

• Testosterone normalization: 87% of participants achieved eugonadal Cavg in the pivotal trial
• Psychosexual improvement: Sustained gains in sexual activity, desire, and function (PDQ) through 24 months
• Lean body mass: +3.15 kg at 12 months (p < 0.0001)
• Bone mineral density: Spine +0.018 g/cm2, hip +0.012 g/cm2 at 12 months (p < 0.0001)
• No hepatotoxicity: No clinically significant liver toxicities in any oral TU clinical trial
• Non-injection route: Eliminates injection-related complications (pain, hematoma, infection at injection site)
• No transference risk: Unlike topical gels, no risk of inadvertent transfer to household contacts

Potential hematologic advantage: Cleveland Clinic clinicians have noted early indications that oral testosterone may cause fewer hematologic side effects (erythrocytosis) than injections and other long-lasting TRT formulations, possibly because the shorter-acting pharmacokinetic profile produces less sustained erythropoietic stimulation [10]. This observation requires confirmation in comparative trials.

Risks, Side Effects & Safety

The Basics

Like all forms of testosterone therapy, Jatenzo carries real risks that require ongoing monitoring. The most common side effects in clinical trials included blood pressure increases, elevated red blood cell counts (hematocrit), headaches, decreased HDL ("good") cholesterol, nausea, PSA increases, mild liver enzyme elevations, swelling, and joint pain.

The blood pressure effect deserves particular attention. Men in the clinical trial experienced average systolic blood pressure increases of 3 to 6 mmHg, which is modest but clinically relevant for men who already have high blood pressure. About 7% of trial participants needed to start or increase blood pressure medication during the study. If you have uncontrolled hypertension, your provider should carefully weigh this risk before prescribing Jatenzo.

A note on the July 2025 label update: the FDA removed Jatenzo's boxed warning for blood pressure increases, removed the separate cardiovascular risk warning section, and removed the contraindication for "age-related hypogonadism." These changes reflect an evolving understanding of the risk profile but do not mean these risks no longer exist. Blood pressure monitoring remains important.

The Science

Common adverse reactions (incidence >= 2%) from prescribing information [1]:

• Blood pressure increase
• Hematocrit increase
• Headache
• HDL cholesterol decrease
• Nausea
• PSA increase
• Transaminase increase
• Edema
• Joint pain (arthralgia)

Blood pressure elevation:
The inTUne trial demonstrated mean systolic BP increases of 3-6 mmHg, with greater magnitude in men with pre-existing hypertension. 7.2% of participants required initiation or escalation of antihypertensive therapy [5][7]. A separate Tlando ambulatory BP study (n=128) reported +4.3 mmHg systolic and +1.4 mmHg diastolic [5]. Kyzatrex showed more modest increases (+1.7-1.8 mmHg systolic) [5].

Polycythemia and hematologic effects:
Testosterone stimulates erythropoiesis via increased erythropoietin production and hepcidin suppression [9]. Hematocrit monitoring is mandatory: check at baseline, 3-6 months after initiation, then annually. A hematocrit exceeding 54% is the threshold for dose reduction, temporary discontinuation, or therapeutic phlebotomy [1].

Cardiovascular safety (TRAVERSE context):
The TRAVERSE trial (n=5,246) is the largest RCT designed to assess cardiovascular safety of testosterone therapy. The primary MACE composite endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) showed non-inferiority of testosterone gel vs placebo (HR 0.96, 95% CI: 0.78-1.17) over 33 months in men aged 45-80 with cardiovascular risk factors [9]. However, TRAVERSE also noted numerically higher incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. TRAVERSE tested transdermal gel, not oral TU; the cardiovascular risk profile of oral TU specifically requires further study.

Venous thromboembolism: DVT and PE have been reported with testosterone products. The mechanism may involve erythrocytosis-related hyperviscosity and testosterone effects on thromboxane A2 release [1][5].

Hepatic safety: Jatenzo is NOT a 17-alpha-alkylated androgen. Pooled safety data from studies of modern oral TU formulations show no clinically significant hepatotoxicity. Liver function test values are not generally associated with oral TU formulations [3][11].

Prostate: Monitor for BPH worsening. Evaluate for prostate cancer prior to initiating and during treatment. PSA monitoring per age-appropriate guidelines [1].

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're noticing acne, water retention, mood changes, or any other shift, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also tracks your hematocrit and PSA values over time, alerting you when levels approach thresholds that need attention.

Dosing & Treatment Protocols

The Basics

Jatenzo dosing starts at 237 mg twice daily (morning and evening), always with food. After 7 days, your provider should check your testosterone level at exactly 6 hours after the morning dose. Based on that result, they may adjust your dose up or down using a structured titration scheme.

The dose range spans from 158 mg twice daily (minimum) to 396 mg twice daily (maximum, which requires taking two 198 mg capsules at each dose). Your provider adjusts the dose to keep your 6-hour post-dose testosterone level between 425 and 970 ng/dL.

The timing of your blood draw is critical and is one of the most common sources of confusion with Jatenzo. Unlike injectable testosterone, where a trough level (drawn just before your next injection) is the standard, Jatenzo uses a 6-hour post-morning-dose level that captures the declining portion of the daily curve. Drawing blood at the wrong time produces misleading results and can lead to incorrect dose adjustments.

Both the morning and evening doses should be the same strength. Take each dose with a meal that contains some dietary fat to ensure adequate absorption.

The Science

Dose titration protocol (from prescribing information) [1]:

Dosage forms:

• 158 mg capsule: opaque red, imprinted "158" in white
• 198 mg capsule: opaque white, imprinted "198" in red
• 237 mg capsule: opaque orange, imprinted "237" in white

Monitoring schedule for dose adjustment:

• Wait minimum 7 days after initiation or dose change before measuring
• Draw serum testosterone 6 hours after morning dose
• Use plain tubes, clotted at room temperature for 30 minutes prior to centrifugation
• Both morning and evening doses must be the same strength [1]

Fat intake guidance: While precise gram targets are not specified in the prescribing information, clinical data indicate that higher fat content improves absorption. A 30 g fat meal provides approximately 25% greater testosterone exposure compared to a 15 g fat meal [5].

Getting the dosing right often takes time and fine-tuning with your provider. Keeping an accurate record of what you're actually taking, when you take it, and what you ate with it makes that process smoother. Doserly tracks your testosterone doses alongside everything else in your health stack, so your full protocol is always in one place.

Never wonder whether you took your dose or when your last one was. The app logs every dose with a timestamp and sends reminders when your next one is due, helping you maintain the consistency that makes testosterone therapy most effective and keeps your levels stable.

What to Expect / Timeline

Days 1-7: Most men will not notice dramatic changes in the first week. Some report a mild energy surge 2-3 hours after each dose as testosterone peaks. This early surge typically normalizes as the body adjusts. Your provider should order blood work after day 7 (6 hours post-morning dose) to assess initial response and determine if dose adjustment is needed.

Weeks 2-4: If absorption is adequate, some men begin noticing subtle improvements in energy and mood. Morning erections may begin to return. Some men experience initial side effects such as headache, nausea, or mild blood pressure increases during this period. These are often transient.

Months 1-3: Sexual desire and function improvements typically become more consistent during this period, as seen in the inTUne trial's psychosexual outcome data. Hematocrit should be checked at the 3-month mark. Blood pressure monitoring should be ongoing. Dose titration may still be in progress.

Months 3-6: By this point, dose titration is usually complete and levels should be stable. Men with adequate absorption typically report their most noticeable improvements in this window. Body composition changes (increased lean mass) begin to become measurable. If testosterone levels remain below target despite maximum dosing (396 mg BID), absorption failure should be considered and alternative delivery methods discussed with your provider.

Months 6-12: Continued gradual improvement in bone mineral density. Lean body mass gains plateau at their new higher baseline. Psychosexual improvements are well-established and sustained. Annual monitoring parameters should be assessed (hematocrit, PSA, lipids, blood pressure).

Beyond 12 months: The 24-month extension data from the inTUne trial confirms that benefits are sustained with continued use. Ongoing monitoring remains important. Discuss long-term treatment goals with your provider at each annual review.

Fertility Preservation & HPG Axis

Exogenous testosterone, regardless of delivery route, suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback on GnRH pulse frequency. This results in decreased LH and FSH secretion, which causes intratesticular testosterone to drop dramatically (normally 40-100 times higher than serum levels). The consequence is Sertoli cell dysfunction and suppression of spermatogenesis. Approximately 40-60% of men on testosterone therapy achieve azoospermia (zero sperm count) within 6 months, with the remainder typically showing severe oligospermia [9].

This applies to Jatenzo. The prescribing information explicitly warns that "spermatogenesis may be suppressed through feedback inhibition of pituitary FSH which could possibly lead to adverse effects on semen parameters including sperm count" [1].

Key fertility guidance for men considering or currently on Jatenzo:

• Before starting: Men who desire current or future fertility should discuss fertility preservation with their provider before initiating any form of TRT. Sperm banking (cryopreservation) should be offered as an option.
• HCG co-administration: Human chorionic gonadotropin (HCG) mimics LH and can help maintain intratesticular testosterone and spermatogenesis during TRT. This is commonly used by providers focused on fertility preservation, though it is not part of the standard Jatenzo prescribing protocol.
• Alternative approaches: For men with secondary hypogonadism who prioritize fertility, alternatives to exogenous testosterone include clomiphene citrate and enclomiphene citrate, which stimulate endogenous testosterone production via the HPG axis while preserving or enhancing spermatogenesis.
• Recovery after discontinuation: Spermatogenesis recovery after stopping TRT is variable. Recovery typically takes 6-24+ months and is not guaranteed in all cases. Factors affecting recovery include duration of TRT use, age, and pre-TRT hormonal status. Men with primary hypogonadism have limited recovery potential.

For detailed guidance on fertility considerations during TRT, see our dedicated guides on HCG, Clomiphene, Enclomiphene, and Fertility Preservation on TRT.

Interactions & Compatibility

Drug-Drug Interactions [1][12]:

• Insulin and oral antidiabetic drugs: Testosterone may decrease blood glucose levels and reduce insulin requirements. Monitor blood glucose closely when initiating or adjusting Jatenzo in diabetic patients.
• Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, edoxaban): Testosterone may increase sensitivity to anticoagulants. More frequent INR or coagulation monitoring is recommended.
• Corticosteroids: Concurrent use may enhance sodium and water retention (edema risk).
• 5-alpha reductase inhibitors (finasteride, dutasteride): These block conversion of testosterone to DHT. The interaction is pharmacologically expected but not well-studied with oral TU specifically.

Supplement Interactions:

• DHEA: May increase total androgen load. Concurrent use with TRT is generally not recommended without provider oversight.
• Boron: May affect SHBG and free testosterone levels. Effects during concurrent TRT are poorly characterized.
• Zinc: Important cofactor for testosterone synthesis; supplementation unlikely to be harmful during TRT but unlikely to add benefit beyond correcting deficiency.

Lifestyle Factors:

• Alcohol: Chronic heavy alcohol use suppresses testosterone production and liver function. Moderate consumption during TRT should be discussed with your provider.
• Exercise: Resistance training and regular physical activity can enhance the benefits of TRT on body composition and cardiovascular health.
• Sleep: Adequate sleep is essential for hormonal health. TRT may improve sleep quality but monitor for sleep apnea exacerbation.
• Body composition: Obesity reduces testosterone levels and may affect oral TU absorption. Weight management supports TRT effectiveness.

Decision-Making Framework

Making the decision to start oral testosterone therapy involves several considerations beyond just a low number on a lab test.

Diagnostic criteria: The Endocrine Society recommends confirming hypogonadism with at least two morning serum total testosterone measurements below the lower limit of normal (typically < 300 ng/dL), combined with symptoms consistent with testosterone deficiency. The cause of low testosterone (primary vs secondary) should be investigated before defaulting to treatment.

When oral TRT may be particularly appropriate:

• Men who are averse to needles or unable to self-inject
• Men who have experienced hematocrit elevation on injectable testosterone
• Men concerned about transference risk with topical gels (especially those with young children)
• Men who prefer the convenience and discretion of an oral medication

When oral TRT may NOT be the best choice:

• Men who do not reliably eat twice daily (absorption requires food)
• Men who have difficulty with medication adherence (twice-daily dosing)
• Men on tight budgets without insurance coverage (list price approximately $1,000/month)
• Men who have previously tried oral TU without adequate absorption response

Questions to discuss with your provider:

• What type of hypogonadism do I have, and has the underlying cause been investigated?
• Is there a reversible cause (weight, sleep apnea, medications) that should be addressed first?
• Given my cardiovascular and prostate risk profile, is TRT appropriate for me?
• Which delivery method best fits my lifestyle, medical history, and fertility goals?
• What will the monitoring schedule look like?

Administration & Practical Guide

Oral administration for Jatenzo is straightforward, but there are important details that affect how well the medication works:

1. Always take with food. This is not a suggestion. Jatenzo requires dietary fat for proper absorption. A meal or substantial snack containing fat (examples: eggs, avocado, peanut butter, cheese, fish) at each dose time is essential.
2. Take twice daily. One dose in the morning with breakfast, one dose in the evening with dinner. Aim for roughly 10-12 hours apart. Both doses should be the same capsule strength.
3. Swallow capsules whole. Do not chew, crush, or open the capsules. They are liquid-filled soft gelatin capsules designed to work as a complete unit.
4. Consistent timing. Try to take your doses at the same times each day. Consistency helps maintain more stable testosterone levels throughout the day.
5. Blood draw timing. For dose adjustment: blood must be drawn exactly 6 hours after the morning dose, in plain tubes, clotted at room temperature for 30 minutes before centrifugation. Incorrect timing produces misleading results.
6. Missed dose. If you miss a dose, take it as soon as possible with food. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double up.
7. Storage. Store at room temperature 68-77 degrees F (20-25 degrees C). Avoid exposure to moisture. Keep out of reach of children.

Monitoring & Lab Work

Pre-treatment baseline labs:

• Total testosterone (2 morning measurements on separate days, confirming < 300 ng/dL)
• Free testosterone
• LH, FSH (to distinguish primary vs secondary hypogonadism)
• Estradiol
• SHBG
• CBC with hematocrit
• PSA (age-appropriate)
• Lipid panel
• Comprehensive metabolic panel (liver function, kidney function, glucose)
• Blood pressure

Initial monitoring (first 3-6 months):

• Serum testosterone: 6 hours post-morning dose after day 7, then as needed during titration
• Hematocrit: at 3-6 months
• Blood pressure: at each visit, and self-monitoring recommended
• Lipid panel: after dose stabilization
• PSA: per age-appropriate guidelines

Ongoing monitoring:

• Hematocrit: every 6-12 months (action threshold >54%)
• PSA: per guidelines
• Blood pressure: at every visit
• Lipid panel: annually
• Liver function tests: while not expected to be abnormal with non-17-alpha-alkylated oral TU, periodic monitoring is reasonable given the oral route
• Symptom assessment: at each visit
• Annual review: reassess treatment goals, benefits, and ongoing need

Estrogen Management on TRT

All testosterone formulations, including oral TU, undergo aromatization to estradiol via the aromatase enzyme, primarily in adipose tissue. Estradiol plays important physiological roles in men, including bone density maintenance, cardiovascular protection, and cognitive function. It is not inherently harmful and most men on TRT do not need estrogen management.

Clinical guidelines (Endocrine Society, AUA) do not recommend routine aromatase inhibitor (AI) use during TRT. Estradiol monitoring is indicated only if symptoms suggest elevated estrogen, such as gynecomastia, significant fluid retention, or emotional lability.

Some TRT clinics and online men's health communities routinely prescribe anastrozole (0.25-0.5 mg 2-3 times weekly) to target a specific estradiol range, often cited as 20-35 pg/mL on the sensitive assay. The clinical evidence does not support this approach for most men, and excessive estrogen suppression is associated with decreased bone density, joint pain, adverse mood effects, and paradoxically decreased libido.

For Jatenzo specifically, the short half-life and pulsed delivery pattern may result in different aromatization dynamics compared to injectable esters, though this has not been formally studied.

Stopping TRT / Post-Cycle Considerations

If you stop taking Jatenzo (or any form of testosterone), your body needs time to restart its own testosterone production. The HPG axis was suppressed during treatment and will need to recover. This process is variable and depends on several factors.

What to expect when discontinuing:

• Testosterone levels will drop within days of stopping oral TU (much faster than with injectable esters due to the short half-life)
• Symptoms of low testosterone may return (fatigue, low libido, mood changes)
• LH and FSH production gradually resumes as the HPG axis recovers
• Full recovery may take 6-24+ months and is not guaranteed

Recovery depends on:

• Duration of TRT use (longer duration generally = slower recovery)
• Age at discontinuation
• Whether you have primary hypogonadism (testicular failure, limited recovery) vs secondary (pituitary/hypothalamic, better prognosis)
• Pre-TRT hormonal status

Post-TRT recovery support (discuss with provider):

• HCG taper to stimulate LH receptors during transition
• Clomiphene or enclomiphene to stimulate the HPG axis
• Gradual dose reduction rather than abrupt cessation (provider discretion)

For more information, see Stopping TRT & Post-Cycle Recovery.

Special Populations & Situations

Obese Men

Obesity is a common cause of low testosterone (functional hypogonadism). Weight loss alone can normalize testosterone in many obese men. Oral TU absorption may be affected by GI physiology in obese individuals. Clinical guidelines recommend addressing weight and metabolic health before defaulting to TRT.

Men with Sleep Apnea

Testosterone may worsen obstructive sleep apnea (OSA). CPAP compliance should be optimized before and during TRT. Monitoring for OSA symptoms is part of standard TRT care.

Men with Cardiovascular Risk Factors

The TRAVERSE trial provides reassurance regarding MACE in men with cardiovascular risk factors, but the blood pressure elevation associated with oral TU specifically (3-6 mmHg systolic with Jatenzo) requires careful consideration. Men with uncontrolled hypertension should have blood pressure managed before starting Jatenzo.

Men with Prostate Cancer History

Current evidence does not support a causal link between TRT and prostate cancer initiation. However, TRT is contraindicated in men with known or suspected prostate cancer. Men with a history of treated prostate cancer should be managed in close collaboration with their urologist.

Men with Type 2 Diabetes

Testosterone deficiency is common in men with type 2 diabetes. TRT may improve insulin sensitivity and metabolic markers. Monitor blood glucose closely, as insulin and oral antidiabetic dosing may need adjustment.

Transgender Men

Jatenzo and other oral TU products are used by transgender men for hormone therapy. Dosing goals may differ from cisgender hypogonadal men. Fertility counseling before initiation is particularly important. Several community reports document positive experiences with Jatenzo in this population.

Older Men (>65)

The distinction between age-related testosterone decline and true hypogonadism is clinically important. Jatenzo is specifically indicated for hypogonadism with confirmed laboratory deficiency, not for age-related decline. The benefit-risk calculus in older men should include cardiovascular risk stratification.

Regulatory, Insurance & International

United States:

• FDA-approved: March 27, 2019 (NDA206089)
• DEA Schedule: III (CIII)
• Manufacturer: TOLMAR Inc. (Fort Collins, CO)
• Label revision: July 2025 (boxed warning removed, contraindication for age-related hypogonadism removed)
• Prior authorization frequently required by insurers
• Average list price: approximately $1,000/month
• Manufacturer savings program available (eligible patients may pay as little as $0-$10 copay)
• No generic available; patents expected to expire around 2030

Insurance challenges:
Insurance coverage for Jatenzo is often difficult to obtain as a first-line treatment. Many plans require step therapy (trial of injectable or topical testosterone first) before covering oral TU. Exceptions may be granted for patients with documented contraindications or intolerance to other formulations.

Cost comparison with other oral TU products:

• Jatenzo: historically the highest-priced oral TU (~$1,000/month list)
• Kyzatrex: self-pay only, approximately $150/month (simplest to obtain)
• Tlando: variable insurance coverage, competitive pricing with copay assistance

International availability:
Jatenzo is specifically a US product. Outside the US, oral testosterone undecanoate is available under different brand names (Andriol/Andriol Testocaps in Europe, Canada, Australia), though these are different formulations with different pharmacokinetics and are not interchangeable with Jatenzo.

Travel considerations:
Testosterone is a controlled substance in most countries. When traveling with Jatenzo, carry the original prescription bottle with pharmacy label, bring a letter from your prescriber confirming the prescription, and research the controlled substance regulations of your destination country.

FAQ

Q: Is Jatenzo bad for my liver?
A: No. Unlike older oral testosterone pills (methyltestosterone) that caused liver damage, Jatenzo is absorbed through the intestinal lymphatic system and bypasses the liver entirely. Clinical trials and pooled safety data have shown no clinically significant liver toxicity with Jatenzo or other modern oral testosterone undecanoate products.

Q: Can I take Jatenzo without food?
A: Taking Jatenzo without food dramatically reduces absorption because the medication relies on dietary fat to form the chylomicrons that carry it into your bloodstream through the lymphatic system. Always take it with a meal containing some fat.

Q: Why does my blood need to be drawn exactly 6 hours after the morning dose?
A: Jatenzo produces a rise-and-fall testosterone pattern throughout the day. The 6-hour post-dose measurement captures a standardized point on the declining curve, allowing your provider to make accurate dose adjustments using the FDA-approved titration table. Drawing blood at different times produces results that cannot be reliably interpreted.

Q: How does Jatenzo compare to testosterone injections?
A: No large head-to-head trial has compared Jatenzo to injectable testosterone. Both effectively raise testosterone levels, but they differ in pharmacokinetics (injections provide more stable levels; oral TU creates daily peaks and troughs), convenience (oral vs. injection), cost (Jatenzo is typically more expensive), and side effect profiles (oral TU may cause less erythrocytosis; injections avoid food-dependent absorption variability).

Q: Will Jatenzo affect my fertility?
A: Yes. Like all forms of exogenous testosterone, Jatenzo suppresses the HPG axis and can significantly reduce or eliminate sperm production. If you want to have children now or in the future, discuss fertility preservation options with your provider before starting any form of TRT.

Q: Why is Jatenzo so expensive?
A: Jatenzo is a brand-name medication with active patents (expected to expire around 2030). No generic version is available yet. The manufacturer offers a savings program that can significantly reduce out-of-pocket costs for eligible patients with private insurance. Kyzatrex, a similar oral TU product, is available at approximately $150/month as a self-pay option.

Q: Can I switch between Jatenzo and other oral testosterone products (Kyzatrex, Tlando)?
A: These products are not bioequivalent and cannot be directly substituted. Each has different pharmacokinetics, dosing, and titration protocols. Switching requires starting the new product's titration protocol from the beginning, with appropriate monitoring.

Q: Does Jatenzo cause blood pressure problems?
A: Jatenzo can raise blood pressure modestly (average 3-6 mmHg systolic). This is more pronounced in men with pre-existing hypertension. The FDA removed the boxed warning for blood pressure in July 2025, but monitoring remains important, especially in the first months of treatment.

Q: Is Jatenzo a steroid?
A: Testosterone is technically a steroid hormone, but Jatenzo provides testosterone at replacement doses designed to restore normal physiological levels, not the supraphysiological doses used in performance enhancement or bodybuilding. It is a legitimate FDA-approved medication prescribed for a diagnosed medical condition.

Q: Can I stop Jatenzo and restart my own testosterone production?
A: In most cases, your body can eventually resume testosterone production after stopping TRT, but recovery takes 6-24+ months and is not guaranteed. Men with primary hypogonadism (testicular failure) may have limited recovery potential. Discuss with your provider before stopping.

Myth vs. Fact

Myth: Oral testosterone pills destroy your liver.
Fact: This was true of older 17-alpha-alkylated oral androgens like methyltestosterone. Jatenzo is a fundamentally different drug that bypasses the liver through lymphatic absorption. Pooled safety data from clinical trials of modern oral TU formulations show no clinically significant hepatotoxicity.

Myth: TRT causes heart attacks.
Fact: The TRAVERSE trial (n=5,246), the largest RCT designed to assess cardiovascular safety of testosterone therapy, found no significant increase in major adverse cardiovascular events (HR 0.96, 95% CI: 0.78-1.17) in men with cardiovascular risk factors over 33 months. TRAVERSE did note higher rates of atrial fibrillation and pulmonary embolism. Earlier observational studies that raised cardiovascular concerns likely reflected healthy user bias and confounding.

Myth: Once you start TRT, you can never stop.
Fact: TRT can be discontinued, and the HPG axis can recover, though recovery takes time (typically 6-24+ months) and is not guaranteed. The decision to continue or stop TRT should be made with your provider based on your diagnosis, symptoms, and treatment goals. For men with primary hypogonadism (testicular failure), long-term or lifelong TRT may indeed be necessary.

Myth: TRT causes prostate cancer.
Fact: Current evidence does not support a causal link between TRT and prostate cancer initiation. PSA monitoring during TRT is a standard safety practice, not an indication that TRT is dangerous to the prostate. TRT is contraindicated in men with known or suspected prostate cancer, but this is a precautionary measure, not evidence of causation.

Myth: All oral testosterone products are the same and interchangeable.
Fact: Jatenzo, Tlando, and Kyzatrex are all oral testosterone undecanoate but have different formulations, different pharmacokinetics, and different dosing protocols. They are not bioequivalent and cannot be substituted for one another. Switching requires re-titration.

Myth: If your lab numbers are good on Jatenzo, you should feel great.
Fact: Testosterone levels measured at one point (especially Jatenzo's 6-hour post-dose peak measurement) may not reflect your overall daily exposure. Some men achieve good peak levels but have troughs that are too low. Oral TU creates a daily pulsed pattern, and subjective response depends on the entire 24-hour profile, not just one measurement.

Myth: All men over 40 with fatigue need TRT.
Fact: Fatigue has many causes including sleep disorders, thyroid problems, depression, obesity, and medication side effects. A gradual decline in testosterone is a normal part of aging and is not the same as hypogonadism. TRT is indicated only for men with confirmed low testosterone on laboratory testing combined with symptoms consistent with deficiency.

Myth: Higher doses of testosterone are always better.
Fact: Testosterone therapy targets physiological replacement (normal range), not maximization. Supraphysiological doses increase risk of adverse events (polycythemia, cardiovascular events, mood disturbance) without proportionally increasing benefit for most men. With Jatenzo specifically, the maximum dose of 396 mg BID already represents the upper boundary of physiological replacement.

Sources & References

Clinical Guidelines

[1] JATENZO Prescribing Information. TOLMAR Inc. NDA206089. Revised September 2025. Available via DailyMed (NLM).

Landmark Trials and Systematic Reviews

[2] Rosen SH, Asanad K. Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex. Medicines (Basel). 2025;13(1):1. doi:10.3390/medicines13010001. PMID: 41562957.

[3] Patel M, Muthigi A, Ramasamy R. JATENZO: Challenges in the development of oral testosterone. Int J Impot Res. 2022;34:721-724. doi:10.1038/s41443-021-00461-4. PMID: 34354245.

[4] Shackleford DM, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration. J Pharmacol Exp Ther. 2003;306:925-933. doi:10.1124/jpet.103.052522.

[5] Swerdloff RS, Wang C, White WB, et al. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab. 2020;105:2515-2531. doi:10.1210/clinem/dgaa238.

[6] Swerdloff RS, Dudley RE. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther Adv Urol. 2020;12:1756287220937232. doi:10.1177/1756287220937232.

[7] Honig S, Gittelman M, Kaminetsky J, et al. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety. J Sex Med. 2022;19:1750-1758. doi:10.1016/j.jsxm.2022.09.002. PMID: 36266204.

[8] Swerdloff RS, Amory JK, Dobs AS, Wang C, Danoff TM, Dudley RE. SAT-044 Treatment of Hypogonadal Men with a New Oral Testosterone Undecanoate (TU) Formulation Improves Psychosexual, Well-Being and Body Composition and Bone Density Parameters. J Endocr Soc. 2020;4:SAT-044. doi:10.1210/jendso/bvaa046.1297.

[9] Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. doi:10.1056/NEJMoa2215025.

Safety Reviews

[10] Cleveland Clinic ConsultQD. Oral Medication Offers New Option for Testosterone Replacement. February 2024.

[11] Goldstein I, et al. Newer formulations of oral testosterone undecanoate: development and liver side effects. Sex Med Rev. 2025;13(2). doi:10.1093/sxmrev/qeae065. PMID: 39291780.

Clinical Practice Guidelines

[12] Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. doi:10.1210/jc.2018-00229.

Related Guides & Cross-Links

Same Category (Oral Testosterone)

• Testosterone Undecanoate Oral (Kyzatrex)
• Testosterone Undecanoate Oral (Tlando)
• Testosterone Undecanoate Oral (Andriol)
• Oral Testosterone Guide

Related Treatment Options

• Testosterone Cypionate (Depo-Testosterone)
• Testosterone Enanthate (Delatestryl)
• Testosterone Undecanoate Injectable (Aveed/Nebido)
• Testosterone Gel (AndroGel)
• Testosterone Injections Guide
• Testosterone Gels & Topicals Guide

Complementary Approaches

• HCG (fertility preservation during TRT)
• Clomiphene (Clomid) (alternative to exogenous T for fertility-preserving treatment)
• Enclomiphene (selective estrogen receptor modulator)
• Anastrozole (Arimidex) (aromatase inhibitor)
• Fertility Preservation on TRT
• TRT Blood Work Guide
• TRT for Beginners

Educational

• The TRAVERSE Trial Explained
• TRT Myths vs Facts
• Stopping TRT & Post-Cycle Recovery
• Estrogen Management on TRT